Locus Biosciences bags up to $12.1M for CRISPR antibacterial; Old Vertex drug heads to PhIII for dementia

In its latest effort to spur the development of new antibacterial drugs, the non-profit CARB-X is awarding Locus Biosciences up to $12.1 million for its CRISPR Cas-3-enhanced bacteriophage for serious recurring urinary tract infections (rUTIs).

EIP Pharma has reported new positive data for an old Vertex drug and hopes to send it into Phase III next year.